Amendments to the claims

Please amend claims 52, 56, 59, 63, 67, and 69.

Please cancel claims 53-55 and 64-65

Please add new claims 71-77.

1-51. **(Canceled)**

52. **(Currently Amended)** A composition comprising active lymphotoxin-β-receptor immunoglobulin (LT-β-R-Ig) fusion proteins and inactive LT-β-R-Ig fusion proteins, wherein no more than 10% ~~30%~~ of the LT-β-R-Ig fusion proteins are inactive.

53-55. **(Canceled)**

56. **(Currently Amended)** The composition of claim 52 ~~any one of claims 52-54~~, wherein the active LT-β-R-Ig fusion proteins are recognized by a functional specific antibody.

57. **(Currently Amended)** The composition of claim 52 ~~any one of claims 52-54~~, wherein the LT-β-R-Ig fusion protein comprises ~~an~~ a human Fc domain.

58. **(Previously Presented)** A pharmaceutical composition comprising the composition of claim 57, and a pharmaceutically acceptable carrier.

59. **(Currently Amended)** The composition of claim 52 ~~any one of claims 52-54~~, wherein the Fc domain is of an IgG1 isotype.

62. **(Previously Presented)** A pharmaceutical composition comprising the composition of claim 59, and a pharmaceutically acceptable carrier.

63. **(Currently Amended)** A composition comprising active and inactive lymphotoxin-β-receptor immunoglobulin (LT-β-R-Ig) fusion proteins, wherein no more than 10% ~~30%~~ LT-β-R-Ig fusion proteins are inactive, and wherein the active LT-β-R-Ig fusion proteins are obtained by culturing a mammalian host cell transformed with DNA encoding

the LT-β-R-Ig fusion protein in a culture system having a temperature of about 27° C to less than about 30 ~~35~~° C

64-66. **(Canceled)**

67. **(Currently Amended)** The composition of claim 63 ~~any one of claims 63-66~~, wherein the LT-β-R-Ig fusion protein comprises ~~an~~ a human Fc domain.

68. **(Previously Presented)** A pharmaceutical composition comprising the composition of claim 67, and a pharmaceutically acceptable carrier.

69. **(Previously Presented)** The composition of claim 67 ~~any one of claims 63-66~~, wherein the Fc domain is of an IgG1 isotype.

70. **(Previously Presented)** A pharmaceutical composition comprising the composition of claim 69, and a pharmaceutically acceptable carrier.

71. **(New)** The composition of claim 52, wherein the active LT-β-R-Ig fusion proteins are glycosylated.

72. **(New)** A composition comprising active lymphotoxin-β-receptor immunoglobulin (LT-β-R-Ig) fusion proteins and inactive LT-β-R-Ig fusion proteins, wherein no more than 6% of the LT-β-R-Ig fusion proteins are inactive.

73. **(New)** The composition of claim 72, wherein the LT-β-R-Ig fusion protein comprises a human Fc domain.

74. **(New)** The composition of claim 72, wherein the active lymphotoxin-β-receptor immunoglobulin (LT-β-R-Ig) fusion proteins are glycosylated.

75. **(New)** A pharmaceutical composition comprising the composition of claim 72, and a pharmaceutically acceptable carrier.

76. **(New)** The composition of claim 73, wherein the Fc domain is of an IgG1 isotype.

77. **(New)** A pharmaceutical composition comprising the composition of claim 76, and a pharmaceutically acceptable carrier.